PMPC - Personalized Medicine and Cancer

Personalized medicine proposes to
improve the delivery of healthcare
by tailoring decisions and therapies
epigenetic information obtained
from each patient’s tissues. Among
all disease areas, nowhere has the
impact of personalized medicine
been greater than in cancer. The
molecular mechanisms leading to
cancer are complex and influenced by
intrinsic genetic and environmental
factors that underlie the diverse
responses to treatments. A better
understanding of these factors will
optimize the treatment selection for
each patient.
The right drug, for the right patient,
at the right time
This project is made possible
through the financial support from
the Ministère de l’économie, de
l’innovation et des exportations du
Québec (MEIE).
Role of the PMPC
There are many challenges to the implementation
of personalized medicine in our healthcare system.
These barriers are being addressed through the
various studies supported by the PMPC project:
Development and consolidation of integrated
clinical and biomarker platforms: the integrated
network and technology platform supports PMPC
project goals and the deployment of personalized
medicine in the healthcare system.
Development of numerical and decision-making
solutions: the initiative expands and implements
electronic and numerical solutions to support
dataflow and analysis to facilitate timely medical
decisions for optimal therapeutic outcomes.
Demonstration of the health economic, ethical
and legal impacts of personalized medicine
solutions applied to the Québec healthcare
Development, validation and commercialization
of cancer biomarkers: tissue genomic and blood
proteomic biomarker signatures are developed to
predict response to drugs for lung, colon, breast
cancers and neuroendocrine tumors.
Studies Supported
by the PMPC Project
The PMPC will help advance our tools and
knowledge to reshape the way doctors approach
and select treatments, provide health and quality
of life benefits to patients, ease the economic
burden imposed on our healthcare system while
supporting a recognized niche of expertise in
Québec. The following studies are supported
through the PMPC project:
•Validation and cost effectiveness assessment
of a blood-based biomarker panel for the
assessment of lung nodules
•Prospective health economic and clinical
outcome study of crizotinib treatment in nonsmall cell lung carcinoma
•Identification of tissue and blood based
biomarkers for resistance to crizotinib treatment
in non-small cell lung carcinoma
•Development of biomarkers for the selection of
colorectal cancer patients responsive to OCZ103-OS
•Development of treatment resistance biomarkers
for aflibercept treatment in colorectal cancer
•Prospective cost effectiveness and clinical
outcome of aflibercept treatment for colorectal
•Development of treatment resistance biomarkers
for vectibix in colorectal cancer
•Prospective cost effectiveness and clinical
outcome of vectibix treatment in advanced
colorectal cancer
•Validation of blood biomarkers for the diagnosis
and treatment of neuroendocrine tumors
•Implementation of a translational database to
support personalized healthcare in Québec
•Proposal for a framework for the reimbursement
of diagnostic tests in Québec
•Development of an initiative for evidence
development in real life situation in support of
coverage for drugs and diagnostic technologies
in Québec
•Assessment of the impact of personalized
medicine implementation on data confidentiality
and risk evaluation for insurance purpose
Origin of the initiative
The Personalized Medicine Partnership for Cancer (PMPC) is a public private
partnership that stemmed from the Stratégie québécoise de la recherche et
de l’innovation (SQRI) created by the Government of Québec to accelerate the
deployment of personalized medicine solutions by addressing barriers to the
deployment of personalized healthcare.
Adriana Aguilar, Hôpital général juif, Centre de
recherche translationnelle sur le cancer de McGill,
Centre du cancer Segal
Jason Agulnik, Chef adjoint, Division des maladies
pulmonaires, Département de médecine, Hôpital
général juif Gerald Batist, Co-Directeur, Q-CROC, Professeur
en oncologie , Université McGill, Directeur, Centre
du Cancer Segal
Mark Basik, Hôpital général juif, Centre de
recherche translationnelle sur le cancer de McGill,
Centre du cancer Segal
Luc Bélanger, Co-fondateur, Q-CROC
Mélanie Bourassa-Forcier, Professeure, Université
de Sherbrooke et Chercheuse associée, CIRANO
Victor Cohen, Hôpital général juif, Professeur
adjoint, Départements d’oncologie et de médecine Christian Couture, Institut Universitaire de
Cardiologie et de Pneumologie de Québec
Louis Gaboury, Directeur, Département de
pathologie et biologie cellulaire, Université de
Yann Joly, Directeur de recherche du Centre de
génomique et politiques, Université Mc Gill
Jean Lachaine, Président, PériPharm et Faculté de
pharmacie, Université de Montréal
Sylvie Mader, Chercheur, Institut de Recherche en
Immunologie et cancérologie, titulaire, Professeur
titulaire, Département de Biochimie, Université de
André Robidoux, Directeur, Groupe de recherche
en Cancer du sein, Centre hospitalier de l’Université
de Montréal, Département de Chirurgie, Université
de Montréal.
Benoit Samson, Hématologue et oncologue,
Centre intégré de cancérologie de la Montérégie
du CSSS Champlain-Charles-Le Moyne
Alan Spatz, Directeur, Département de pathologie,
Hôpital général juif
Leon van Kempen, Hôpital général juif, COO
et Directeur scientifique, Centre de pathologie
The right drug, for the right patient, at the right time
Accelerating precision medicine through proteomics and immune monitoring
CLIA Diagnostics
PROTEOCARTA, is a gelfree, label-free mass
spectrometry platform enabling
comprehensive and quantitative
measurements of proteins
across large sets of samples
for the discovery and validation
of biomarkers.
IMMUNECARTA is a proprietary
immune monitoring platform
offering 14 color, multiparametric
flow cytometry for functional
analyses of complex innate and
adaptive immune responses.
Caprion’s diagnostic initiatives
are focused on programs that
leverage and enhance Caprion’s
existing core proteomics
competencies for biomarker
discovery in tissues (secretory
vesicles) and plasma with the
use of multiplexed MRM assays
for rapid biomarker verification
and validation.
•Over 15 years working with
leading pharmaceutical and
biotech companies to discover
and validate new biomarkers
and drug targets
•Expertise in targeted
proteomics using highly
multiplexed MRM assays
for biomarker development
and validation
•Greater reproducibility,
throughput, and multiplexing
capabilities with MRM assays
than competing technologies.
•GLP operation with rigorous
•Immune Oncology, Vaccine,
Infectious Disease, and
Autoimmune expertise
•Pre-clinical and clinical
trial experience
•GLP operation with
rigorous QA/QC
•Differentiated ability to
rapidly develop and validate
customized complex assays
for clinical studies
•New ways to monitor
complex immune functions
•Partnering with over
50 pharmaceutical and
biotech companies
Current active programs for
in vitro diagnostics product
development include:
»»Lung nodules
»»Neuroendocrine tumors
•Infectious diseases
»»Lyme disease
»»Pediatric fever
»»Disease progression
»»Drug response prediction
Proven track-record
of proteomics expertise
CLIA Diagnostics
Trusted immune monitoring
partner for vaccine and
therapeutic development
Delivers the promise of
“Lab-to-Clinic” testing
For more information:
Patrick Tremblay – Caprion Senior Vice-President, Corporate Development and Diagnostics
M: (514) 513-1998 • [email protected] •